BLGO

julian_jakobi

I remember well when you had so many questions and we DMed before you invested. :) FYI - I did screenshots of your knowledgable BLGO basher endorsement, unreal.

dbixon

He said they have watched the stock fall 80% and decided they’re “not touching this shit.” Shit = stock. I know English isn’t your first language; that’s how English works. You can twist and interpret however you want, but as soon as you deviate from the words he used, you lose the right to call him a liar. You know what’s really sad? I want BLGO to do well! I own shares myself! I hate that there’s a bear case at all. And yet here I am fighting you because you lie and mislead while falsely accusing others of doing so. And you’ll never admit you were wrong; you’re obviously in capable of that. As for being surprised, I sure hope you’re right. But you’ve been saying stuff like that for several years. One simply needs to search for BLGO in this sub to find years and years of you pumping this stock and giving assurances that improvement is coming soon. Lies and misleading, right Julian? No of course not, not from you, everyone who disagrees with you yeah they lie, but not you, never you.

julian_jakobi

Lies and intentionally misleading to discredit BLGO. Let others judge if that is what he said or not. For me this is what he tried to communicate that no insider is investing. A lie. I think you might be wrong with your statements. Read my post again and maybe you’ll understand “on track”.

dbixon

“Insiders won’t put their money in” is obviously not a good summary of what he said since insiders have made private investments, as you pointed out. He said insiders haven’t bought BLGO STOCK! STOCK!!! STOCK!!!!!!! STOCK!!!!!!!!!!!!! **HE SAID STOCK!!!!!!!!!!!!!!!** You don’t get to change what somebody says and then call them a liar based on your revision. That’s not how it works. And Clyra is absolutely not on track since BioClynse was originally supposed to be launched in 2025, then in Q1/Q2 2026, then by July 4th 2026, and now in Q4 an FDA application hasn’t been submitted yet which means it won’t be launched until 2027 at the earliest. They’re not on track.

dbixon

Yes, the purpose of a bearish post is to put the company in a bad light. Isn’t the point of your bullish posts to put BLGO in a good light? You originally claimed he said, “Insiders won’t put their money in,” which you called a lie, and you justified your accusation by pointing to private investments made in Clyra. I responded “he never said ‘Insiders won’t put their money in’” and referred to what he DID say, which is that insiders haven’t purchased BLGO in over two years, which is factually correct. He did not lie; your accusation was the lie. I know he didn’t spend a lot of time with it because he *said it was AI slop.* And since I was able to generate a multi-page bearish report using a brief AI prompt as well (which took me about five minutes), I know it didn’t take him much time. You create biased pieces and spread them to pump the stock all the time. I don’t see why you feel compelled to attack somebody for doing the same thing you do (only bearish). By the way, over on Stocktwits you are claiming the Clyra launch is “on track,” which is obviously a lie.

julian_jakobi

The whole purpose was to put BLGO into a bad light. I pointed the lies and misleading out with direct quotes from the text that I summarized previously. Things you claimed he never said - but he did- yet you still defend it.

dbixon

\> Why do you defend him? Already covered this.... I defend the \*truth\*. You accused him of lying, I defended against that accusation. \> Calvert personally invested in Clyra financings, and Clyra’s CEO also invested. Those are not open-market BLGO purchases, but they directly contradict the claim that insiders’ own money is not touching the enterprise. He said no insider has purchased the stock in over two years. You called that a lie. IT'S NOT A LIE! He said "Insiders have watched this stock fall 80% and decided their own money isn't touching this shit." The stock. The STOCK! THE STOCK!!!!!!! You even frickin acknowledge that your counter-examples are NOT THE STOCK, "those are not open-market BLGO purchases." It's right there, in your own words! **NO INSIDER HAS PURCHASED THE STOCK IN OVER TWO YEARS!** That is factually correct, not a lie. \> They were compensation shares, but they were also subject to a lock-up. So he received shares (didn't buy them).... as deferred compensation... deferred meaning withheld until a specific time or event in the future.... which you agree with! And you still accuse him of being misleading?!?! What he stated was FACTUALLY CORRECT. \> Yet you did not point out any of his many lies or misleading statements. As I've gone to great lengths to explain, the closest thing I found to a "lie" in his comment was he rounded the current and 52-week low stock prices to two decimals. And honestly I don't consider rounding a lie. So no, I didn't find any lies or misleading statements in his comment. \> You defend and endorse them. I defend and endorse the truth, whatever that is. \> It seems very fishy. You think everything is fishy. Struggling with paranoia? \> You also owe... I don't owe anything. I said I COULD reproduce his information with a basic AI prompt if necessary, but given your own propensity for using AI, I encouraged you to try it out yourself. Which you did! You reverse-engineered his comment and saw quite a simple AI prompt akin to, "give me a bear case for BLGO, use all recent publications, cite your sources, and take the tone of a pissed off retail investor." A significant portion of the rest of what you came up with was very specific instruction like "be sure to include "HARD AVOID" at the bottom" which he could have very well added himself. He didn't invest a lot of time and energy in his comment.... hell, he even admitted at the top that it was AI slop! Are you suffering from dementia? That would make a lot of sense. The paranoia, delusions of grandeur, false accusations... my father has dementia and I'm noticing a lot of similar behavior. If so, I'm really sorry, and I hope you're able to find some peace while you battle such a debilitating disease.

julian_jakobi

**ONE OF MANY -** Why do you defend him? **YOU defended him like this:** 1. He never said, "Insiders won't put their money in." You even put it in quotes! What he actually said was "insiders have not put a single dollar of personal cash into the stock in over two years," which is factually correct. 1. **Yes he did**. **original posted text: “The people closest to every contract, every lab result, and every cash-flow number have watched this stock fall eighty percent and decided their own money isn’t touching this shit.”**   Calvert personally invested in Clyra financings, and Clyra’s CEO also invested. Those are not open-market BLGO purchases, but they directly contradict the claim that insiders’ own money is not touching the enterprise. You defended him like this: 1. He stated quite clearly "Calvert received 919,483 shares in equity grants ... as deferred compensation." When you exclude the "deferred compensation" piece, yes it would be misleading, but the poster included that, so no, not misleading at all. **Original posted text “Calvert received 919,483 shares … deferred compensation, not a man betting his own savings at the bottom.”**   **CLEARLY MISLEADING** They were compensation shares, but they were also subject to a lock-up until BioLargo reports $40 million in consolidated gross revenue, exceeds a $300 million market cap, or has a change in control. The post omits that he cannot simply sell the shares into the market. **He won't see a cent until the market cap 12Xs or revenue 10Xs - He is betting his annual salary AND invested $1/4 Million directly into CLYRA** **3. YOU AGREED - MISLEADING** 1. "Eight weeks of cash" - I agree this can seem misleading, but higher in his post regarding the burn rate, he said "**At that pace** the cash is gone in approximately 2.2 months," which seems reasonable for an AI to calculate. I'll give you this one anyway. **It goes on like this. Point by point.** OP u/[dbixon](https://www.reddit.com/user/dbixon/) you make a public post recommending to put BLGO on their watchlist - yet you did not point out any of his many lies or misleading statements (listed above)- but you even endorsed them. Please explain - **it seems very fishy.** You also owe all the biased false or misleading details that ID posted that **you said would appear from even a basic prompt and that you could share.**

ThrowRA91041

And here we have the weekly BLGO pumper post

julian_jakobi

ONE OF MANY **“The people closest to every contract, every lab result, and every cash-flow number have watched this stock fall eighty percent and decided their own money isn’t touching this shit.”**   Calvert personally invested in Clyra financings, and Clyra’s CEO also invested. Those are not open-market BLGO purchases, but they directly contradict the claim that insiders’ own money is not touching the enterprise.

julian_jakobi

$BLGO latest Form 4 matters: CEO Dennis Calvert knows best about what is happening behind the curtains and he just took 931,886 shares at $0.08 for accrued salary/expenses—not cash—and they are locked until BLGO reaches $40M in revenue, a $300M market cap, or a change of control. This follows his latest annual compensation award— no cash but 919,483 shares—under the same lock-up framework. That does not guarantee results, but it does show management is accepting restricted equity rather than cash and tying its upside to meaningful execution. At today’s \~$25.7M market cap, the $300M unlock is \~11.7x, or roughly $0.94/share. It means that he won’t see a penny until those benchmarks of \~ 10X in revenue or \~ 12x in market cap are reached. Some smart investors might want to take advantage of those signals.

dbixon

Instead of accusing the bear-case-presenter of "lies and misleading", why not address some of the issues he brought up? For instance: Why hasn't any insider purchased BLGO stock on the open market in 2+ years? You've mentioned before that you have open lines of communication with management; have you ever asked them why they're not buying at 52-week lows? What is Clyra spending so much money on if they're not processing new orders for ViaClyr? What exactly is the hold-up for getting BioClynse submitted to the FDA?

julian_jakobi

My AI reverse engineered that prompt. Just to show you that it did not get to the same conclusion like you. It says that something similar must have been promoted. “Analyze BioLargo, Inc. (OTCQX: BLGO) as an investment as of October 1, 2026. Research the latest SEC filings, Form 4 insider filings, share-price history, company announcementsy, and September 2026 investor town hall. Verify every material number against its source. Focus on the Pooph licensing and payment dispute; the change in quarterly revenue; June 30 cash, operating cash burn, working capital, and stockholders’ equity; outstanding warrants and likely financing needs; Clyra Medical’s ownership and management’s stated valuation; and whether insiders have made open-market purchases. **Write a bearish investment takedown titled “My AI Slop Analysis: BLGO — BioLargo, Inc.” Open with a one-line verdict. Make the argument feel like a sharp, frustrated retail investor explaining why the stock is dangerous—not a neutral analyst report. Use specific figures, dates, calculations, and parenthetical references to SEC filings. Write in punchy paragraphs with occasional profanity, vivid phrasing, and an unequivocal final verdict of “HARD AVOID.” Do not include generic investment disclaimers or a balancing bull-case section.** **OP** **Why do attack me but you endorse and defend biased BS that came out from something like that?** Do better man.

dbixon

“I put the quotes to show what the point was.” So you changed what he said to match what you thought his points were in order to call him a liar. That’s called strawmanning. I’ll say this again: when you insert yourself in every BLGO-relevant conversation on Reddit and attack naysayers with false accusations, not only do you make yourself look bad, you make BioLargo look bad too. Do better man.

dbixon

Thank you for complying. I find it very unfortunate that you're now on record, in public, accusing this person of making statements he never made. I'll address each of your citations: 1. He never said, "Insiders won't put their money in." You even put it in quotes! What he actually said was "insiders have not put a single dollar of personal cash into the stock in over two years," which is factually correct. 2. He stated quite clearly "Calvert received 919,483 shares in equity grants ... as deferred compensation." When you exclude the "deferred compensation" piece, yes it would be misleading, but the poster included that, so no, not misleading at all. 3. "Eight weeks of cash" - I agree this can seem misleading, but higher in his post regarding the burn rate, he said "**At that pace** the cash is gone in approximately 2.2 months," which seems reasonable for an AI to calculate. I'll give you this one anyway. 4. "Financing stops because warrants are underwater." -- Again, putting something in quotes he never said. I can't find where he even implied this. What he did say was raising money "through warrant exercises" stops because "every outstanding warrant is dead at $0.08." 5. "A new BLGO equity offering is unavoidable." You called this unsupported, but he quite clearly said "the math demands one" and provided support justifying his claim. 6. "No signed partners or contracts." -- He never said this. 7. "No financing supports the $100M Clyra valuation." - He explained in detail why he feels the $100M Clyra valuation is suspect. 8. "Negative book equity proves Clyra can't be worth $100M". - He never said it \*proves\* anything, he just referenced it as reason to think the $100M valuation is bullshit. 9. "Revenue down 55%" was mentioned at the end of the Pooph paragraph, so wasn't intended to "tell the whole story." And revenue was indeed down 55% due to the loss of Pooph, so factually correct. 10. "Pooph stole or reverse-engineered the formula." -- Again, he never said that. What he said was: "quietly developing a replacement formula the whole time," and "reverse-engineered their way out of it." As Pooph is still on the market today, presumably with a different formula, this is apparently exactly what Pooph did. 11. "Pooph stole Biolargo's brand." -- He never said this either. He said Pooph "walked off with the brand", which they did. 12. "$0.08 is exactly the 52-week low." -- You got him there... unfortunately it's actually lower. And today's closing price is slightly above $0.08, but rounds down to that number according to standard arithmetic. 13. "Everyone who looked carefully sold, and they were right." -- You claimed this was opinion presented as fact. He actually said: "It is priced like everyone who looked carefully already said fuck it and sold, and they were right." Seems quite clearly an opinion presented as an opinion to me. I sincerely hope BioLargo turns this ship around, which is what they have to do, and no amount of pumping or falsely accusing naysayers of lying is going to help (in my opinion).

julian_jakobi

Ok. Lies and misleading are: \- \*\*“Insiders won’t put their own money in.” False.\*\* Calvert personally invested $241,000 in Clyra financings. Those were notes with warrants, not open-market BLGO purchases. \- \*\*“Calvert’s 919,483 shares were just grants.” Misleading.\*\* He accepted shares for salary and expenses owed to him. They are locked up until BioLargo reports $40 million in consolidated gross revenue, exceeds a $300 million market cap, or undergoes a change in control. The revenue target is about \*\*8×\*\* the post’s roughly $5 million annualized Q2 revenue run rate; the market-cap target is about \*\*11.5×\*\* its cited $26 million market cap. The filing permits the revenue target to be met in a reported quarter \*or\* year—it does not say annual revenue only. \- \*\*“Eight weeks of cash.” Misleading.\*\* The post treats historical consolidated cash use as a precise ongoing runway. Calvert put parent-company operating costs at roughly $250,000 a month. Neither figure alone proves a company-wide runway. \- \*\*“Financing stops because warrants are underwater.” False.\*\* Those warrants are not BioLargo’s only potential funding source. \- \*\*“A new BLGO equity offering is inevitable.” Unsupported.\*\* More funding may be needed, but its form and timing are unknown. \- \*\*“No signed partners or contracts.” False as a company-wide claim.\*\* Clyra has distribution agreements, and BioLargo has disclosed engineering contracts. Agreements are not guaranteed sales. \- \*\*“No financing supports the $100 million Clyra valuation.” Misleading.\*\* Management tied that indicative figure to outside investors’ private Clyra transactions. It is not a guaranteed sale price. \- \*\*“Negative book equity proves Clyra cannot be worth $100 million.” False.\*\* Book equity is not a market valuation. \- \*\*“Revenue down 55%” tells the whole story. Misleading.\*\* Losing Pooph drove the year-over-year decline; Q2 revenue also grew 12% sequentially. BioLargo is still unprofitable. \- \*\*“Pooph stole or reverse-engineered the formula.” Unproven.\*\* Those are disputed claims, not established findings. \- \*\*“Pooph stole BioLargo’s brand.” Misleading.\*\* Pooph owned the brand; BioLargo supplied technology and product. \- \*\*“$0.08 is exactly the 52-week low.” Inaccurate as stated.\*\* Available September 29 quotes showed a close above $0.08 and a lower 52-week low. \- \*\*“Everyone who looked carefully sold” and “already priced in.” Opinion presented as fact.\*\* The post supplies no evidence for either claim.

dbixon

Not sure why you're winking at me, but you're welcome to try this out yourself. Go to your favorite LLM (I tried ChatGPT just now), and simply say: "Present a bear case for why people should avoid investing in BioLargo (BLGO). Be as detailed as possible and include recently-published statements and events." I got a result back even more detailed and thorough than RedPlumpTomato's.

dbixon

\> What if it is all real this time and they'll deliver in time or are even a few steps further than you state? That's the kind of good news that can and should inspire new investors to hop in. As I said above, if this was the first time blast-off news was "right around the corner," I'd be encouraging the speculative types out there to buy now. But the current landscape of retail investors is full of folks who already did that and now regret it (and I'm admittedly one of them), so I can't in good conscience recommend others follow suit. I believe there will be plenty of time to initiate a position if "it's all real this time".... maybe a few pennies higher than 8c, but that's a reasonable price to pay for some assurance. \> I strongly disagree that longtime holders will automatically hand new investors an easy entry at $0.15. That's fine. I certainly don't think \*all\* of them will, but I've heard from dozens of investors who have stated their plan to break-even. Perhaps you aren't hearing from those folks for some reason. \> Why would the most convicted holders sell at $0.15 just as the path to a much larger valuation come into view? I'm not talking about the most convicted holders. In my opinion, it's important to focus on the norm rather than extreme cases, and most retail investors would not describe themselves as "most convicted". \> The stock traded in the $0.40s when the commercial story was still largely anticipation. That's exactly the problem! The commercial story has been "largely anticipation" for two years now. People bought back in 2024 because someone told them blast-off news was right around the corner, and when that didn't materialize, they lost interest and sold. Hopefully all of that interest will return when the commercial story goes from anticipation to realized, but there are a lot of sour bagholders out there right now. \> Waiting until everyone agrees it's happening may mean missing the moment when the market reassesses BLGO. I think "everyone agreeing it's happening" is the same thing as "market reassesses BLGO." Again, if this were the first time the "commercial story" was considered imminent, I'd be much more aligned with your thinking. Personally, I think trying to convince people to buy now (before the thesis is proven out) sounds a lot like a bagholder trying to create exit liquidity for himself, and folks are wary of that sort of thing. If the Cinderella story plays out, new investors will have an opportunity to get in on the 2nd floor, and all those "most convicted holders" will be elated as well... Everybody wins. \> I am adding heavily. That's great! I don't know what "heavily" means to you, but less than $5k has traded today as of this writing and it's up 7%, so you could probably gobble up the ASK through $0.12 pretty easily if you wanted.

julian_jakobi

This helps. Thanks. I certainly agree with your suggestion to put it on the watchlist not to miss when the big turnaround will happen. But what if it is all real this time and they’ll deliver in time or are even a few steps further than you state? BTW I strongly disagree that longtime holders will automatically hand new investors an easy entry at $0.15. People who have followed BioLargo for 3, 5, 10 or 15 years aren’t all waiting for the first bounce so they can break even. Many are waiting for the catalyst that could finally change what this company is. If Clyra’s launch becomes real, why would the most convicted holders sell at $0.15 just as the path to a much larger valuation comes into view? IMHO years of DD will result in adding not selling. This stock traded in the $0.40s when the commercial story was still largely anticipation. Imagine what could happen if a major Clyra launch actually materializes. That’s the bullish case: not that success is guaranteed, but that waiting until everyone agrees it’s happening may mean missing the moment when the market reassesses BLGO. That being said - I am already adding heavily. 😉

dbixon

I really can't argue with anything you've shared, and don't intend to try. The bear case, presented here in a no-nonsense fashion I appreciate, is exactly why I'm encouraging new investors to **watch, not buy**. BioLargo has to get its shit together, and if they manage to do that, then they'll be worth a closer look. $BLGO could turn into quite the Cinderella story.... but they have to get an invitation to the ball first. By the way, thank you for identifying your comment as "AI Slop Analysis" - I think some people forget how easy it is to generate such prose with a brief AI prompt these days.

dbixon

Hello "fellow investor". Happy to give my thoughts: \> CEO said... Does that suggest Clyra may be further along than your write-up assumes? Unfortunately BioLargo has a very long history of projecting-then-failing aggressive timelines. For example, around this time last year, the CEO said he thought the BioClynse launch would take place in Q1/Q2 of 2026, which obviously didn't happen. I've spoken with their IR representative (from Darrow) about this, and he said that unexpected delays tend to happen when involved with a partner whose decisions are made independently, as is the case here (CEO has confirmed it's entirely in the partner's hands). Because of this, **my write-up doesn't assume any particular timeline, only stating that submission for FDA approval is due "soon".** \> A fellow large investor believes that Clyra will be worth well north of $500 million... do you think that is a realistic outcome? That would be great, and I'm certainly not ruling it out, but for now Clyra has to get its product on shelves first. Echoing what I said previously, BioLargo has a very long history of offering large potential valuations and peppering their presentations with "best-case-scenario" numbers. One particular investor has gone to great lengths to saturate social media with these wishful projections (maybe we're talking about the same person). While I appreciate that person's persistence and thoroughness, I think some damage has been done, as all of their projections have fallen short thus far and people grow tired of the boy who cried wolf. After all, the stock is at an all-time low. That person's believers are all currently holding bags and rightfully upset at the moment, which is why **I'm encouraging potential investors to watch for now, not buy.** Perhaps things would be different if this was the first time blast-off news was "right around the corner" rather than the fifteenth time. \> What would be your trigger to buy? Focusing on Clyra/BioClynse, I offer four triggers to buy depending on your risk profile: Aggressive = when the FDA application is submitted, Medium = when the FDA submission comes back approved, or Conservative = when the first material purchase order is made (which should align with identifying the major partner), or Super-Conservative = when first revenue is reported. FDA review typically takes 90 days, so that's plenty of time right there for medium-risk investors to noodle. \> If investors wait until recurring revenue is obvious, do you think the risk/reward will still be as attractive? I believe so, yes. 8c/shr may (hopefully) be the ground floor, but new investors can wait until this hits 15c (45M market-cap) and still get in lower than most current shareholders. Given how depressed existing shareholders are at the moment, I anticipate some "break-even" selling as the stock begins to rise, creating enough liquidity for new investors to hop in before it (hopefully) rockets. \> Could much of the repricing occur between now, launch confirmation, and the first visible sales ramp? Anything's possible, but I highly doubt it. What would be the catalyst for such a repricing? As I said before, this isn't the first time in BioLargo's history that blast-off news is "right around the corner." One merely has to search for $BLGO here on reddit to see. Even if someone claimed to have insider information and the FDA application was being submitted tomorrow, I doubt that would move the needle much, as there have been too many head-fakes. This is why **I'm encouraging potential investors to watch for now, not buy**. If BioLargo's thesis ever begins to legitimately take off, there will be plenty of time and liquidity to secure a decent entry point. Hope this helps!

julian_jakobi

🤣 Bro wrote a full forensic autopsy of an eight-cent stock he says he wouldn’t touch. Did BLGO reject your application, or did Pooph leave you on read? I get the bear case. The cash burn is real, and Pooph was a mess. But spending this much energy on a stock you supposedly don’t want - then assigning zero value to everything that hasn’t hit the income statement yet - is a pretty funny way to announce you’re not interested. **HARD AVOID**, yet here you are tracking the town hall, counting Calvert’s shares, and doing warrant math like BLGO owes you closure. **Be honest: you’re watching for the same catalysts the bulls are**. You just wrote a breakup letter first.

RedPlumpTomato

My AI Slop Analysis: **BLGO -- BioLargo, Inc.** \## One-liner verdict Nineteen years public, never a profit, barely two months of cash left, and a customer who built an empire on their chemistry and then stole it — HARD AVOID. BioLargo has been publicly traded since 2007 and has never once turned a fucking profit. The stock is at $0.08 right now — not near its fifty-two-week low but literally on it, the exact low set August 20, 2026. It was forty cents in February 2024. That eighty-percent collapse happened while management filed press release after press release about PFAS remediation breakthroughs, wound care devices, and battery storage partnerships. The science may be real. The business has not figured out how to make money from any of it across nineteen years. The fastest way to understand what happened to the revenue is Pooph. Pooph Inc. was a pet-odor brand that licensed BioLargo's chemistry, became their single biggest customer, and drove quarterly revenue to $2.777 million in Q2 2025. Then Pooph stopped paying royalties in August 2025, quietly developed a replacement formula the whole time, terminated the agreement, walked off with the brand, and left BioLargo holding $3.763 million in unpaid receivables — $1.378 million in royalties and $2.385 million in product invoices — for which BioLargo established a full credit loss provision (10-Q, EDGAR 0001437749-26-028023). Some bastard built a pet-odor empire on BioLargo's work, reverse-engineered their way out of it, and ghosted a three-million-dollar bill. Q2 2026 revenue: $1.248 million. That is a fifty-five percent year-over-year collapse. There are no confirmed near-term catalysts that change the math here, and that is worth saying plainly — there is not a goddamn hard-dated event in the next sixty days. Management mentioned an October consumer relaunch at their September 10 town hall — their own microphone, their own audience, no signed contract, no named distribution partner, not backed by inventory on order. The PFAS engineering business is genuinely growing. It is growing off a small base while the parent company burns through cash at a pace that makes slow organic growth irrelevant. ALREADY PRICED IN at eight cents. The cash emergency is happening right now. $2.188 million in the account at June 30, 2026, against operating burn of $5.973 million in the first half of the year — roughly $3 million per quarter. At that pace the cash is gone in approximately 2.2 months. They survived H1 by raising $4.469 million through warrant exercises and subsidiary capital raises. Here is where that shit stops: the April 2026 warrant prospectuses show exercise prices from $0.19 to $0.33, weighted average around $0.265 (424B4 filings, EDGAR, April 2026). Every outstanding warrant is dead at $0.08. A new equity offering is coming because the math demands one, and existing shareholders take the dilution. The balance sheet is broken everywhere you look. Stockholders' equity is negative $1.852 million. Working capital is negative $1.266 million. Enterprise value at verified net debt runs to roughly $29 million — nearly six times the annualized quarterly revenue run rate of about $5 million. Expensive as shit for a company with negative equity, no working capital, and a cash account ticking toward zero. Share count is 328.7 million and only goes higher. Institutional ownership is 0.036 percent.

julian_jakobi

100% my take on it. I did plenty of hours of DD on this. Mark when we have had this conversation. BLGO at 0.09 Let’s see what the future will bring. As you could read - I believe it is a great opportunity.

julian_jakobi

🚨 Reminder: [$BLGO](https://stocktwits.com/symbol/BLGO) earnings call + shareholder townhall today BioLargo will review Q2 2026 financial results, recent milestones, and hold an extended public Q&A. 🗓️ Thursday, Sept. 10 ⏰ 1:00 PM PT / 4:00 PM ET 🎥 Webcast: [webcaster5.com/Webcast/Page...](https://stkt.co/R9nf5Y23) Join a few minutes early to register and make sure the webcast is working. Looking forward to hearing the update and the answers to the questions from shareholders.

julian_jakobi

Big PR just came out: $BLGO: BioLargo Canada + Fort McKay’s Indigenous-led Tũ Nipi partnership targets Alberta oil-sands process water, PFAS and industrial wastewater. Commercial trials are underway, supported by a conditional ERA grant within a CAD $4.6M project. Massive tailings-water market + real local partner. Bullish. FULL CIRCLE 😉 It actually makes waiting so much easier when you are heavily invested in something purposeful. Step by step to full reevaluation. https://www.newswire.ca/news-releases/biolargo-canada-and-tu-nipi-form-indigenous-led-partnership-to-treat-oil-sands-process-water-and-more-884603211.html

julian_jakobi

😉 I just bought $40k worth of stock. IMHO this is where the big bucks are made. I bought on this dip around $5 at exas- everybody told Me there also that I should move on- that I am just a bagholder etc. I made 2000% returns on that stock. It taught me who laughs last laughs best ;) See that long decline and the dip to $5 (marked) I believe that is where we are with BLGO right now. Set a reminder - BLGO at .095 when we have had this conversation. https://preview.redd.it/xnyrxh7q1joh1.png?width=2524&format=png&auto=webp&s=7380824b8174897923c94b351b0838af01721043 .

julian_jakobi

LOok into BLGO - 30 Million market cap with man solutions for trillion dollar problems - just before commercialization will become visible to the public.

julian_jakobi

Copied from a fellow Bull on stocktwits: $BLGO At \~$26M market cap, BLGO is now valued at only a relatively small premium to the amount of identifiable direct common-stock capital it has raised since inception. At $0.08, you’re paying approximately: $26M equity value for a company that has: \* AEC/PFAS technology \* Clyra \* BETI/Cellinity \* BLEST engineering \* ONM \* existing commercial revenue \* 10,000+ hours of AEC field operation \* multiple technologies being commercialized If commercialization is actually imminent, then this is an amazing time to get in.

King_Bean031

If their medical product were so advanced like you say it is, it would have blown up already. They don't have an edge over their competitors. Same with the PFAS collection. Aecom is a huge company in comparison, nearly $10B market cap. Why the hell would investors look at a company such as BLGO when they don't have anything revolutionary compared to their much larger competitors that already have a strong foothold in the industry? Especially when BLGO as a company came out to say they don't have the profits to cover operations? They're a dying company for a reason.

ExplanationNormal339

[$BLGO](https://aimytrade.io/ticker/blgo?utm_source=reddit&utm_medium=comment&utm_campaign=SmallStreetBets&utm_term=BLGO&utm_content=template_1786277716098_grta6q) sitting right at a level I care about. The reaction to guidance often tells you more than the number.

stumblios

BLGO has been getting posted here for at least 5+ years. I owned it for a brief period in 2022ish. Seems like it is always on the verge of commercial success, then it just doesn't do anything. If they succeed on their in-house commercialization efforts, this could get a quick repricing, but there is no guarantee that roll out goes quick or smooth and there could be some growing pains.

MarmotsRMtnGophers

BLGO commercialization of Clyra.

julian_jakobi

Historically they did best when they leave the selling of their amazing tech to partners. POOPH became a blockbuster success. (before their partner stopped paying). Now they have partnered with a Global leader in clean water tech - AQUATECH that installed thousands of water systems in 60 different countries. They are implementing BLGO PFAS remediation tech into their huge water systems- 7 Bids are out already. Clyra Medical partnered with Al -Hikma the leading medical distribution company in the Middle East. Additionally one of the global top 4 medical companies will release a cobranded product at scale later this year. The engineers just signed a $1.2 Million contract - they almost doubled revenues last year and will likely double this year also. A relaunch of a Pet product seems likely in 2026 also. I am a long term investor and all of the above are things I was waiting for for years. Obviously others lost their patience. BUT I am 100% confident this longterm investment will reward all shareholders plenty. We know what is coming and at a $35 million market cap A LOT of money can be made IMHO 😉 mom and dad companies run out of a garage without any revenue have a higher market cap than that. The reevaluation will be pretty and we know it will happen. Best of luck! Do your Own DD!

LostAbbott

Today had a stupid amount of volume.  We had a similar dip a week or so ago?  I don't know what is going on, but either someone lost patience with the. Company or shorts have started to think the cellar is a good place for Dennis...   I don't know that adding here is the play or just holding to see if we go to .08.  I am average around .16 and could see doubling down at .08 or below...  I have been into BLGO for half a decade at this point.  It always had had a lot of promise paired with failure to launch and over promises...

julian_jakobi

BioLargo Signs Deal To Accelerate Commercialization Of PFAS Treatment Technology **Strategic Partnership Aims to Scale Advanced “Forever Chemicals” Remediation Solutions for Safer Water and Environmental Protection.** By Henry DeVries, Senior Writer, California Business Journal Southern California cleantech company BioLargo and global water purification company Aquatech are collaborating to enable the deployment of technology as a concentration and collection step within Aquatech’s full flowsheet solutions for PFAS treatment, including destruction. “By partnering with Aquatech – one of the most respected and capable organizations in the global water treatment industry – we can significantly amplify the reach and impact of our Aqueous Electrostatic Concentrator technology,” said Tonya Chandler, president of BioLargo Equipment. “Together, we are combining proven engineering, innovative science, and deep market experience to deliver scalable PFAS treatment solutions for industrial, municipal, and government clients.” BioLargo Equipment is a subsidiary of BioLargo, Inc. (OTCQX:BLGO), an environmental engineering company developing and commercializing sustainable technologies, announced it has signed into a memorandum of understanding (MOU) with Aquatech to advance the integration and commercialization of BioLargo’s proprietary Aqueous Electrostatic Concentrator (AEC) for PFAS treatment. BioLargo’s AEC technology is designed to remove per- and polyfluoroalkyl substances (PFAS) from liquid streams, producing treated water suitable for drinking water applications. AEC uses electromotive force to collect and immobilize PFAS directly onto membrane surfaces without generating a secondary concentrated liquid waste stream. This collaboration enhances the two companies’ ability to integrate AEC with Aquatech’s comprehensive, end-to-end PFAS treatment solutions that enable their public and private sector clients to meet evolving regulatory requirements. Aquatech is globally recognized for its technical excellence and innovation in sustainable water and wastewater management and was awarded *Water Technology Company of the Year* at the 2025 Global Water Summit in Paris, France. Aquatech’s industry-leading technology portfolio includes membrane, thermal, biological, electrochemical and ultrapure water treatment solutions. The agreement establishes a non-exclusive framework for collaboration on PFAS treatment projects worldwide, enabling both companies to combine their complementary technologies to better serve the rapidly growing PFAS remediation market. Aquatech International’s corporate headquarters is located in Canonsburg, Pennsylvania, Established in 1981, the company is a global leader in water purification technology for industrial and infrastructure markets, specializing in desalination, water reuse, and zero liquid discharge. “Coupling BioLargo’s AEC PFAS collection and concentration technology with Aquatech’s PFAS removal and destruction expertise presents a powerful opportunity to fast-track effective solutions to serve the customer,” said Devesh Mittal, vice president of Aquatech Environmental Services. *Henry DeVries is a former Forbes online columnist who is the chief book strategist at Indie Books International. He has ghostwritten, co-authored, or edited more than 200 business books, including his international bestseller*, How to Close a Deal Like Warren Buffett*.* *https://calbizjournal.com/biolargo-signs-deal-to-accelerate-commercialization-of-pfas-treatment-technology/*

SpaceMurse

BLGO pamping! Good company too

julian_jakobi

$BLGO the progress is real and not reflected in the price at all: ✅ Lake Stockholm AEC install - done. January 27, 2026. Live. In the ground. Under NJDEP & EPA monitoring. First real-world municipal PFAS deployment. ✅ Clyra first stocking order - secured February 2026 through Advanced Solution’s national US distribution network. Hospitals. Clinics. Revenue starting. ✅ Clyra Al Hikma deal - signed May 5, 2026. Exclusive Middle East + North Africa distribution for ViaCLYR™. GCC, Levant, and adjacent markets. ✅ $1.2M Minerals Contract signed - April 20, 2026 BioLargo Engineering providing its expertise in designing and engineering the pilot-scale facility. ✅ New MOU signed - May 3, 2026. Another AEC partnership in motion (Aquatech) That’s five material updates in roughly 100 days. No guts - No Glory💪🏻 📈

julian_jakobi

$BLGO the progress is real and not reflected in the price at all: ✅ Lake Stockholm AEC install - done. January 27, 2026. Live. In the ground. Under NJDEP & EPA monitoring. First real-world municipal PFAS deployment. ✅ Clyra first stocking order - secured February 2026 through Advanced Solution’s national US distribution network. Hospitals. Clinics. Revenue starting. ✅ Clyra Al Hikma deal - signed May 5, 2026. Exclusive Middle East + North Africa distribution for ViaCLYR™. GCC, Levant, and adjacent markets. ✅ $1.2M Minerals Contract signed - April 20, 2026 BioLargo Engineering providing its expertise in designing and engineering the pilot-scale facility. ✅ New MOU signed - May 3, 2026. Another AEC partnership in motion (Aquatech) That’s five material updates in roughly 100 days. No guts - No Glory💪🏻 📈

julian_jakobi

$BLGO important nuance: Aquatech isn’t just “some partner.” They claim 2,000+ global installations and 1.6B+ gallons treated daily across water systems. Their PFAS full-flowsheet/destruction offering appears custom/project-based, not a mass-produced unit line, but that’s exactly why BLGO’s AEC could matter as a concentration step inside bigger PFAS treatment trains. Big commercialization door opening!!

julian_jakobi

$BLGO important nuance: Aquatech isn’t just “some partner.” They claim 2,000+ global installations and 1.6B+ gallons treated daily across water systems. Their PFAS full-flowsheet/destruction offering appears custom/project-based, not a mass-produced unit line, but that’s exactly why BLGO’s AEC could matter as a concentration step inside bigger PFAS treatment trains. Big commercialization door opening.

julian_jakobi

$BLGO while I was drafting my DD MASSIVE NEWS came in. BioLargo signs MOU with Aquatech to accelerate commercialization of its AEC PFAS treatment technology. This is exactly the kind of validation longs have been waiting for: Aquatech brings global water treatment reach, engineering depth, and PFAS destruction expertise. BLGO brings AEC, a concentration/collection tech designed to remove PFAS without creating a secondary liquid waste stream. Industrial, municipal, government clients. Worldwide PFAS projects. Major commercialization pathway forming. This looks like a very serious step toward scale. This won’t stay a $50 million penny stock for much longer ;) do your own DD! MAximum Bullish. https://www.newswire.com/news/biolargo-signs-memorandum-of-understanding-with-aquatech-to-accelerate

julian_jakobi

Actually one of the multi million shares Biolargo holders points that out all the time. That SCWO has no revenues, only has one solution - that can't even compete with BioLargos tech. Yet they do have a similar market cap to BioLargo, that has revenues, already a commercial municipal installation and multiple best in class solutions in trillion dollar markets.. a massive case for the absurd undervaluation of BLGO.

julian_jakobi

It was only one. Years ago, I loaded up on $EXAS on a dip to $5 - a move that felt uncomfortable at the time but proved to be the right call. My remaining 400 shares were automatically sold a few weeks ago at $105 when the company was acquired. That same gut feeling? I’m getting it now with $BLGO. The current market pricing simply doesn’t reflect what’s happening inside this company. I’m rolling those gains straight into BioLargo - full conviction that higher levels are ahead.

broccoli0302

TLDR: I think things get interesting in about a year. Don’t take my word for it, go check out the filings and news reports about Clyra, AEC, Cupridyne Clean, BLEST, and Biolargo’s battery tech. Let me start by being very clear that I am just some dude and I do not have a background in any of the tech fields that Biolargo is working in. In other words, my answer to your question is based on generalist knowledge that could be very wrong based on not knowing medical supply timelines, etc. That being said, I’m invested and expect a timeline that looks something like below. This quarter is more or less a wash. There will be underwhelming revenue from Clyra because they are JUST getting started and trying to grow market adoption. The AEC in Lake Stockholm won’t do much for revenue either, so I think we’ll still see a net loss of a pretty wide margin as intense cash burn of “go to market” expenditures starts to taper off and revenue hasn’t quite caught up. I see this as the final dilution window where that $10 million stock offer option keeps them going. Next quarter should see Clyra start to come into its own. Their first product, Viaclyr, should see increasing revenue over time for the next several years because it is 1) an amazing product that revolutionizes wound care (not an exaggeration, read what the experts who tried it said) and 2) working its way into markets through sound technical channels. Their second product that they have a “gorilla” partner working on with them is likely to hit either in this or the next quarter given the releases we’ve seen about it. When that happens, we will see real revenue growth. I’ve watched interviews of the Clyra CEO and they have way more than two products in the pipeline so we should see some steady growth from about 2 quarters in the future to about the next 5-10 years without doing anything more than refining production lines. The AEC water treatment system in Lake Stockholm is undergoing a one year performance review by every agency you can think of at federal, state and local levels. The tech is good and should pass with flying colors, they’ve already demonstrated it for years now. Once it is officially field proven, it’s the only thing out there that currently meets FDA PFAS removal requirements. What do I think that means? Not much this year besides whatever the contract with the Lake Stockholm municipality pays, but a potential hockey stick type action following. Basically a near certain 10ish month catalyst. Pair those two catalysts and I think we are going to see the stock trade sideways for about the next two quarters before slowly climbing to about the .18 mark by end of year and then probably taking off about 12 months from now. There are a bunch of other X factors from Cupridyne Clean, the battery play, and their Engineering support contracts, but I am more confident about Clyra and AEC. I will close by saying that I am literally just some dude who reads fanatically about BLGO in his free time but has no expertise in any of this. Do not make a decision based on what I’m saying here. If you think this makes sense, go and read the filing from the company and the press reports about the various products and decide for yourself if I’m off base or on target.

ThrowRA91041

The BLGO shill is back! I bet those bags are heavy.

julian_jakobi

I like the way you’re thinking about focus - it’s exactly the right concern to have with any “platform” story. The key for me is that BioLargo isn’t one small team trying to juggle five ideas at once. It’s a holding company structure with separate, dedicated teams and their own CEOs for the big verticals: PFAS, Clyra Medical, Cellinity, and the engineering group. The core BLGO leadership allocates capital and sets strategy, but execution is pushed down to world‑class operators in each lane, not run out of one overcrowded inbox. So instead of one management team being “spread thin,” you effectively get multiple focused companies under one cheap ticker – each run by people whose full‑time job is to make that vertical work. That structure is exactly why I’m comfortable owning \~1.25% and still adding, rather than worrying they’re trying to do everything with one small generalist team. Each subsidiary has their own website - just check out the team behind Clyra for example: [https://www.clyramedical.com/our-team](https://www.clyramedical.com/our-team) please feel free to ask further questions. - It is so much happening at BioLargo that it is actually fun digging ;)

dbixon

BLGO is a penny-stock that could 50x in the next 3 years *if* any of their technologies get picked up in the marketplace. They’re basically an incubator with four ideas currently being fleshed out. The ideas are: forever-chemical filtration, liquid batteries for long term energy storage, next-gen surgical wound care, and an odor-elimination formula.

LostAbbott

Check out BLGO.  There are a lot of players in the clean water and more importantly PFAS game.  As far as I can tell BLGO likely has the best scale solution at a cheaper price point with less consumables...

Hamzehaq7

man, it's wild how undervalued BLGO seems right now. with all that tech and potential, $55M market cap feels like a joke. like, they've got legit advancements in PFAS removal and wound care that could change the game, but the price isn’t reflecting any of that. maybe the market’s just slow to catch up? idk... but with all those catalysts coming, it could turn around pretty quickly. i'm curious to see how the wound care stuff plays out, especially if it gets more attention. what’s your take on the timeline for those catalysts to kick in?

julian_jakobi

Thanks for the feedback. We have certainly seen higher levels before.. FYI: BioLargo (BLGO) technicals: after a long correction and consolidation, the chart shows a higher low and a tightening triangle, with selling pressure easing and volume stabilizing. First upside target \~0.25, then 0.40 and 0.60 if it breaks out with conviction; downside now looks relatively limited versus upside if commercialization catalysts hit. Do your own DD! https://preview.redd.it/x8nviag2kzpg1.jpeg?width=925&format=pjpg&auto=webp&s=487db15191b497e35bcf7872e7817e608e9473b2

GettinFroggyHere

Check out BioLargo (BLGO). It hasn't done .uch in the last couple of years but they are commissioning their first PFAS system install in NY state, cellinity grid-scale batteries, and just released a medical line up of products such as bandages and wound flush for hospitals. I have no hopes of immediate moon shots, but they seem to be on the cusp of making a ton of money. Their strategy is very investor concious, meaning they want to avoid dilution as part of their plan to scale up. I don't know if that will harm their ability to rapidly scale or not, as they have some creative paths to scale already in the works.

broccoli0302

Biolargo, BLGO. It has been sitting at .18 for months now. Biotech company that does odor removal, best in class PFAS removal, batteries and breakthrough wound care product. People are sleeping on it because of a “go to market” hiccup for their first product that they rolled out under odor control “Pooph” which has been a blocked punt. In the last 60 days they have just brought their PFAS and wound care products to market- first PFAS install in New Jersey and first stocking order for wound care products announced. Market cap at 55 million, both products are potential 3-4X catalysts IMO.

Get_rch_or_try_dyin

They weren’t getting paid . BLGO had to sue and pull their product back

Get_rch_or_try_dyin

Unfortunately the $3mil wouldn’t do much . I love Pooph, and I buy some every time I stop in petsmart. But BLGO really needs to get moving on stuff . I know the Clyra deal was unfortunate. But these guys have been operating for 35 years . At some point you have to get things done, or try something else . I’m rooting for these guys, and I’ve got a friend with a very significant amount of shares , but he’s been holding for like 7+ years now , and nothing has happened.

julian_jakobi

$BLGO step by step. 🚀 [https://www.linkedin.com/posts/dennispcalvert\_leachate-landfill-activity-7431724632354848769-HVLV?utm\_medium=ios\_app&rcm=ACoAAAdd6oMBHkrJzINwZ-5z-8ZtNA8QidL3Aqs&utm\_source=social\_share\_send&utm\_campaign=copy\_link](https://www.linkedin.com/posts/dennispcalvert_leachate-landfill-activity-7431724632354848769-HVLV?utm_medium=ios_app&rcm=ACoAAAdd6oMBHkrJzINwZ-5z-8ZtNA8QidL3Aqs&utm_source=social_share_send&utm_campaign=copy_link) Jul 23, 2025 · Project to develop a leachate treatment system for a client has progressed from bench-scale studies to plans for an on-site pilot, potentially leading to a $3 million full-scale system. “BioLargo has been awarded an additional phase to manufacture and run a pilot scale system onsite for a leachate pretreatment system. This initiative aims to address issues with leachate affecting the UV disinfection system at a local wastewater treatment facility. The company has successfully completed bench-scale testing to enhance transmissivity and is now ready to implement the pilot scale project in Florida.” Also regarding the Clyra launch. We know it’s coming - with a above 100 Billion $ market cap gorilla partner. Do your own DD. This won’t be a below $200 million company for very much longer IMHO. https://preview.redd.it/m1r5ue2uabmg1.jpeg?width=1290&format=pjpg&auto=webp&s=af7433e4cf6f3ca1026cdb245f7e1f094e92a8f2

Get_rch_or_try_dyin

When are they going to grow the business, grow revenue , get contracts , and return value to shareholders ? I think they have a ton of potential. But they need to get something to market or make some money soon. I’m fan and supporter of BLGO. But they need to make something happen soon

julian_jakobi

Great questions. I recommend that you spend the time to dig into it. $BLGO It is about education and patience - a lot of people are still on the sidelines, and as execution and commercialization progress become more visible, the market’s reevaluation could be substantial. Management believes the company is already trading at roughly 3–4x below where it should be and recently raised several million dollars at about this same valuation, which reinforces that view. Best of luck with your investing. https://youtu.be/9mdumBTDCac

julian_jakobi

$BLGO well observed. The progress is real. From simplywallstreet that featured BLGO as one of their favorite picks a couple of days ago: https://preview.redd.it/u5t3rm5w3ybg1.jpeg?width=1290&format=pjpg&auto=webp&s=77e419191675f71282da9e1798d227f0185c5d35

julian_jakobi

They mostly dilute only on the subsidiary level. Clyra revenue are expected to validate a market cap of north of $500 million within 18months. Their cash burn rate is really low. https://preview.redd.it/wug835ag2ybg1.jpeg?width=1227&format=pjpg&auto=webp&s=198fe099eb174d3e23254bacb246cb0f92bb5666 Note that management thinks they should be worth $200 million already. And projected future value is 50-87 x current market cap. The CEO recently addressed everything in a letter to shareholders: [https://feeds.issuerdirect.com/news-release.html?newsid=7448032311850076&symbol=BLGO](https://feeds.issuerdirect.com/news-release.html?newsid=7448032311850076&symbol=BLGO)

julian_jakobi

$BLGO It is about education and patience - a lot of people are still on the sidelines, and as execution and commercialization progress become more visible, the market’s reevaluation could be substantial. Management believes the company is already trading at roughly 3–4x below where it should be and recently raised several million dollars at about this same valuation, which reinforces that view. Best of luck with your investing. https://youtu.be/9mdumBTDCac

dbixon

BLGO has a new wound care solution coming out in partnership with a mega distributor in Q2. Should take the SP from 0.18 to >0.50.

dbixon

BLGO currently 0.18, I expect it over $1, by this time next year.

BlackMaelstrom1

Hurt me again, BLGO.

Get_rch_or_try_dyin

BLGO has massive potential

TheDeHymenizer

BLGO -50% Used to be GORO was down 80% at one point but am now break even and am expecting it to be my best investment ever if I'm reading recent releases correctly.

Own_Lynx_7265

Watching retail flow this morning and it’s a funny combo: **Bullish** * **$BLGO** – PFAS treatment play getting real industry love (AEC). Tiny name, big narrative. * **$ISSC** – literally trading like nobody noticed 20% ROIC + 27% growth. Discounted because it’s boring. * **$SEZL** – officially added to the S&P SmallCap 600. When funds *have* to buy, they buy. * **$NVDA** – China H200 shipments confirmed (again). Data center demand doesn’t care about TikTok bans. **Bearish** * **$PEP** – activist pressure to cut prices. Good for consumers, bad for margins. Pepsi might get “Ozempic’d.” **Neutral (eyes-on)** * **$SPY** – everyone waiting for NFIB + JOLTS + FOMC tomorrow. Market’s on mute mode until data hits. * **$AMD** – still in “regulatory rumor jail” thanks to the NVDA China mess. Could snap either direction depending on clarity.

julian_jakobi

Thanks for letting us know. Maybe, when I’ll get my 3 - 5X untill next summer with BLGO I will diversify a little bit ;)

dbixon

BLGO An incubator with a market cap only $50M. They have new technology approaching commercialization in three distinct fields: long term grid-level energy storage (liquid sodium batteries), forever-chemical filtration of water, and wound care. The wound care solution is launching commercially with a major international distributor in Q2’26. Estimated value of that launch is half a billion, and BioLargo owns 48% (5x current market cap). The forever-chemical filtration system is being installed this very second at its first commercial buyer location (a muni in New Jersey). The EPA is monitoring this as a pilot project. If successful, growth could be pretty rapid as everyone will want to advertise their new PFAS-free water (5x current market cap). Their battery (Cellinity) just passed 3rd party validation and offers significant benefits over current market options (doesn’t catch on fire among other things). Company is actively seeking a partner to build factories; 11 MOU’s signed as of last month. If successful, growth could be pretty rapid as AI energy demands continue (10x current market cap). Currently at $0.18/shr, 52wk low is $0.14 and high is $0.32. With their wound care launch right around the corner, this is an easy one to toss some speculation money at.

LostAbbott

Still just you and me.  I don't know what the deal is with BLGO.  I keep adding at .15ish, but man they just cannot excite.  The earnings call last week was more of the same Calvert always has lots of positive forward looking things to say, but nothing ever comes of it and they cannot exicute on what should be basic things.  POOPH was nothing but fairly weak excuses and "go read the lawsuit".  Yes Clyra sounds game changing, but so do the batteries and the PFAS, the just cannot get things to market and when they do some negative shit happens.  You can just chalk it up to a small company running into typical road blocks, but when you have been with these guys for nearly 5 years the same story over and over again is getting hard to keep buying... 100k, ~.19

stumblios

BLGO has been floating around this sub for at least 5 years now. It always has a story about how "it's finally about to execute the mission!" I've bought into it a couple times. I think I sold once for a mild profit and once for a mild loss. Is this the time that it finally takes off? Maybe, anything is possible. Or this could be another rinse + repeat. I will say, at the very least, you probably won't lose your shirt on this stock. I do believe it's the most stable penny stock I've ever seen. It's been trading between 10-40 cents for at least 7 years. 99% of tickers mentioned in this sub have gone through 3+ reverse splits in that time.

robbur88

This is true. That's why I didn't ask about the other 30 tickers that got spammed to me. I only click the ones with 20+ comments and those tend to be the ones that run. So I looked into BLGO enough that I think I need to return to DD on it later. But was hoping someone would throw a red flag and turn me away.

robbur88

So my feed page always has these randoms. I always assumed they were sponsored bot type stuff. But I started noticing that an odd amount of them getting spammed on runs just days later in here. Anybody looked into BLGO?

sexdick420

Why the long disconnect between FDA approval and product launch? It should have also been worth noting in your DD that Clyra isn’t fully owned by BLGO so what is the profit/revenue split going to look like? Especially since they are now adding a THIRD partner.

LostAbbott

I am not quite on your level of BLGO fandom, but I am still more than most.  I like these guys a lot.  However, the is chart is very crazy.  The number of "ifs" that need to hit for this to be real is pretty crazy...

pigeon_shit

BLGO has leading tech in PFAS removal. They have wear many hats and are way undervalued. Their earnings are also this week.

LostAbbott

Yeah I have a few different PFAS investments.  I like BLGO the best so far, but their process sounds interesting.  I know quite a few folks in Waste Water management and I am skeptical about how they "destroy the PFAS". None of that matters with a reverse splits.  Current shareholder always get wiped out with reverse splits.  Get out and wait for the split to bottom before you get back in.

travis2886

BLGO

travis2886

BLGO

julian_jakobi

Great to hear that you bookmarked it with a some shares. That is a good timeline. Hopefully at that point BLGO will be a multibillion Nasdaq traded powerhouse and I will own an island 🏝️🙋🏼‍♂️😉

RJM145

On paper and in theory I think you’re right and I know that “past performance is not an indicator of future…”. I continue to watch and you’ve given a fair timeline. My thought is about the opportunity cost of waiting for next year as it’s not going to have a UAMY style run up. Therefore, I’ll follow the news and possibly get back in before profitability is announced.  That said, now you got me worried I’ll be missing the boat haha.  I do believe in the company, the leadership and the technology. I’ve literally sat at a Starbucks with the founder/CEO in the early days and he’s as quality of a guy as I’ve met in business.  On a separate note, I’m mostly in mining stocks at this point, majority of which are penny and nearly all have either “silver” or “gold” in the name. So, with many late to that party, I think it has more movement before companies like BLGO, and my hope is to roll profits next year. 

stumblios

Yup, been reading about it being BLGO's time for almost 5 years now. I think it's the most stable penny stock I've ever seen.

dbixon

BLGO is about as low as it’s ever been, and their subsidiary Clyra is gearing up to launch (by next summer) a new product with a major distributor. Hope to see a nice pop by then. They have other pokers in the fire as well but this is the closest to generating substantial revenue in the near-ish term.

julian_jakobi

BLGO as much as I can get at these crazy discounted levels.

julian_jakobi

Look into $BLGO - the deeper you dive the more you will like it!

julian_jakobi

The Pooph licensing saga is a striking validation of BioLargo’s technology—CupriDyne enabled Pooph to achieve blockbuster success and a $50 million run rate in the pet odor market before licensing issues emerged. When Pooph tried to expand beyond its agreed territory and defaulted on payments, BioLargo decisively reclaimed its IP, showing strong management and commitment to shareholder protection. Pooph’s attempts to use BioLargo’s formula (improved formula with the same claims) outside their license will likely result in expensive legal consequences, but the key takeaway is how the tech proved itself in real consumer markets and is now ready for a better, more reliable partner. The revenue will be missed - but last Q it was only 40% of BLGO's revenue - so it was dwindling down already . It certainly was a reason why there was additional pressure on price but that offers an opportunity to add until the obove describd catalysts will become more visible and the upcoming Clyra launch will dwarf the Pooph revenues at peak anyhow.

Gydvinn

You are deeply mistaken. SCWO isn't meant to replace filtration at the front end of drinking water treatment. 374Water’s SCWO units are primarily aimed at: Military and DoD hazardous waste (AFFF foam, munitions cleanup), industrial waste streams, sludge from wastewater treatment , leachate from landfills. SCWO uses energy, but it is often self-sustaining after startup (organics provide thermal energy). SCWO isn’t for swimming pools that BLGO is interested in, it is for toxic sludge, leachate, AFFF waste, and what BLGO can’t handle.

julian_jakobi

Thanks for making the bullish case for BioLargo tech. Pfas is measured in parts per trillion - that means a grain of salt in multiple olympic sized swimming pools. So why would you treat all those swimming pools with A HIGH ENERGY destruction their tech when you could just use a tlow energy tech to collect the Pfas and then use a super oxidation tech to destroy the highly concentrated PFAS. (BLGO has their own tech for that as well). again, would you boil multiple swimming pools just to kill a some tiny "pollutants" - or wouldn't it make more sense to capture those pollutants first and then destruct them?

Gydvinn

Removing PFAS from water is one thing, but the challenge is how you deal with the concentrated PFAS (waste stream, disposal, destruction). SCWO’s claim is that it destroys organic / hazardous compounds (including PFAS) under extreme conditions (supercritical). That’s a different value proposition. So BLGO would need to not just remove PFAS, but responsibly handle or destroy it to fully compete. Aside from that, we first bought the rumor for SCWO. News are coming either today or early next week.

julian_jakobi

You are welcome. Biolargo - $BLGO

TheDeHymenizer

ooohhh another PFAS penny stock - might be a good hedge to my BLGO lol

dbixon

BLGO has a medium term catalyst with their BioClynse wound solution launching in Q1, and their Cellinity energy storage battery tech is a long term play. They’re also focusing on forever chemical water filtration (first project set to go live next week). I’m holding for a double up by summer.

julian_jakobi

I am 95 % in BioLargo. Shifted massive gains between 1200%- 2500% from $exas to $BLGO Accumulated 1.25% of a penny stock company that has yet to explode to the upside. Anything below 20x returns would be a disappointment. But for now an index fund would have been a better investment - but that was the case as well with EXAS - for years - before that started running. BLGO lift off seems very close and with such a commitment it could become life changing gains. Still hold 400 EXaS shares with $5 average.

TheDeHymenizer

Almost guaranteed 3x-4x - ELTP, SEUSF Outside shot 10x+ - GORO, BLGO, NLST

Get_rch_or_try_dyin

One of my friends has a few million shares of BLGO. I use their pooph products almost daily

Get_rch_or_try_dyin

BLGO definitely has huge potential! Wish you could buy it on Rh though. This one will make millionaires

dbixon

BLGO This won’t win your game, but if you’re looking for something to park some money in that could pop in the next 6-12 months thanks to a commercialization launch, it’s a pretty safe gamble.

TheDeHymenizer

I'm in way to many right now hahaha, GORO, ELTP, NLST, BLGO, SEUSF. ELTP is really the only one I believe in long term the other ones are "long term holds" but absolute insane gambles.

dbixon

BioLargo (BLGO) really shouldn’t be as low as it is, but unfortunately one stupid pumper has wrecked its credibility by acting like a used car salesman in all his posts. But the company still shows a lot of promise, with some major catalysts due before spring.

TheDeHymenizer

I take a very different approach to penny stocks then this board. I believe there are amazing opportunities that are being largely ignored by the broader market. Instead of waiting for a big move and then getting out I try to find a small number of stocks that have an outsized risk vs reward and pour hundreds to thousands of dollars in them and then hold for years until the rest of the market catches up. So far here's some results from this strategy GORO - down 10% but had about 30% of my initial cost paid off from dividends before the stock collapsed so I may be up on a total basis. Held since 2019 one of my losers BLGO - down like 50% held a bit over a year ELTP - up 50% SEUSF - Up 100%, was up like 400% at one point NLST - Down about 20% The hope is one day I'll be able to cash out on one of these at like $10 or more per share for an absurd % gain and the winners will pay back any losers and then some. I'm pretty confident on all of these (minus GORO) having the potential too do that at some point. Its just a matter of being patient. I know this is a different strat from what you asked but figured it would help add insight into a different method of approaching penny stocks.